Table 1 Evolution of Mycobacterium chelonae susceptibilities.
From: Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection
M. chelonae Susceptibilities:January 2020 | M. chelonae Susceptibilities:October 2020 | ||
|---|---|---|---|
Agent | MIC1 | Agent | MIC |
Trimethoprim-sulfamethoxazole | 0.5/9.5 | Trimethoprim-sulfamethoxazole | 1/19 |
Linezolid | ≤1 | Linezolid | 4 |
Ciprofloxacin | 2 | Ciprofloxacin | >4 |
Imipenem | 16 | Imipenem | >64 |
Moxifloxacin | 2 | Moxifloxacin | 4 |
Cefoxitin | >128 | Cefoxitin | >128 |
Amikacin | 16 | Amikacin | 16 |
Doxycycline | >16 | Doxycycline | >16 |
Minocycline | >6 | Minocycline | >8 |
Tigecycline | 0.03 | Tigecycline | 0.12 |
Tobramycin | ≤1 | Tobramycin | — |
Clarithromycin | NR | Clarithromycin | >16 |
Clofazimine | — | Clofazimine | <0.015 |
Bedaquiline | — | Bedaquiline | 0.001 |
Omadacycline | — | Omadacycline | 0.06 |
